Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The UK's benchmark FTSE 100 index fell on Wednesday, dragged by healthcare shares after GSK warned of lower annual vaccine ...

The number of ISA millionaires is growing all the time and guess what? They're really into blue-chip dividend shares listed ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

In the third quarter, GSK saw weaker-than-expected sales for its respiratory syncytial virus (RSV) and shingles vaccines.

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

Regeneron and GlaxoSmithKline have joined forces to generate genetic sequence data from the 500,000 volunteers in the UK’s Biobank database. The companies hope the initiative will give insights ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

The market for GSK plc's ( LON:GSK) shares didn't move much after it posted weak earnings recently. We did some digging, and ...

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Looking ahead, revenue is ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...